Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
GREAT network, Sao Paulo, Brazil.
Clin Chem. 2018 Mar;64(3):515-525. doi: 10.1373/clinchem.2017.279513. Epub 2018 Jan 17.
There is concern that high-sensitivity cardiac troponin (hs-cTn) may have low diagnostic accuracy in patients with low acute coronary syndrome (ACS) probability.
We prospectively stratified patients presenting with acute chest discomfort to the emergency department (ED) into 3 groups according to their probability for ACS as assessed by the treating ED physician using a visual analog scale: ≤10%, 11% to 79%, and ≥80%, reviewing all information available at 90 min. hs-cTnT and hs-cTnI concentrations were determined in a blinded fashion. Two independent cardiologists adjudicated the final diagnosis.
Among 3828 patients eligible for analysis, 1189 patients had low (≤10%) probability for ACS. The incidence of non-ST-segment elevation myocardial infarction (NSTEMI) increased from 1.3% to 12.2% and 54.8% in patients with low, intermediate, and high ACS probability, respectively. The positive predictive value of hs-cTnT and hs-cTnI was low in patients with low ACS probability and increased with the incidence of NSTEMI, whereas the diagnostic accuracy of hs-cTnT and hs-cTnI for NSTEMI as quantified by the area under the curve (AUC) was very high and comparable among all 3 strata, e.g., AUC hs-cTnI, 0.96 (95% CI, 0.94-0.97); 0.87 (95% CI, 0.85-0.89); and 0.89 (95% CI, 0.87-0.92), respectively. Findings were validated using bootstrap analysis as an alternative methodology to define ACS probability. Similarly, higher hs-cTnT/I concentrations independently predicted all-cause mortality within 2 years (e.g., hs-cTnT hazard ratio, 1.39; 95% CI, 1.27-1.52), irrespective of ACS probability.
Diagnostic and prognostic accuracy and utility of hs-cTnT and hs-cTnI remain high in patients with acute chest discomfort and low ACS probability.ClinicalTrials.gov Identifier: NCT00470587.
人们担心高敏心肌肌钙蛋白(hs-cTn)在急性冠状动脉综合征(ACS)低概率患者中的诊断准确性可能较低。
我们前瞻性地根据就诊于急诊部(ED)的医师使用视觉模拟量表评估的 ACS 概率将出现急性胸痛的患者分为 3 组:≤10%、11%至 79%和≥80%,在 90 分钟时回顾所有可获得的信息。以盲法测定 hs-cTnT 和 hs-cTnI 浓度。两位独立的心脏病专家裁定最终诊断。
在 3828 例符合分析条件的患者中,1189 例 ACS 概率较低(≤10%)。非 ST 段抬高型心肌梗死(NSTEMI)的发生率分别从 1.3%增加到低、中、高 ACS 概率患者的 12.2%和 54.8%。hs-cTnT 和 hs-cTnI 的阳性预测值在 ACS 概率低的患者中较低,且随着 NSTEMI 的发生率增加而增加,而 hs-cTnT 和 hs-cTnI 对 NSTEMI 的诊断准确性(以曲线下面积(AUC)定量)在所有 3 个分层中非常高且相当,例如,AUC hs-cTnI,0.96(95%CI,0.94-0.97);0.87(95%CI,0.85-0.89)和 0.89(95%CI,0.87-0.92)。使用 bootstrap 分析作为替代方法来定义 ACS 概率,验证了这些发现。同样,较高的 hs-cTnT/I 浓度独立预测了 2 年内全因死亡率(例如,hs-cTnT 风险比,1.39;95%CI,1.27-1.52),与 ACS 概率无关。
在急性胸痛和低 ACS 概率患者中,hs-cTnT 和 hs-cTnI 的诊断和预后准确性和效用仍然较高。
NCT00470587。